Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 20 (July 10), 2006: pp. 3310-3311
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.06.5086

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santillan, A.
Right arrow Articles by Bristow, R. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Santillan, A.
Right arrow Articles by Bristow, R. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

CORRESPONDENCE

In Reply

Antonio Santillan, Robert E. Bristow

The Kelly Gynecologic Oncology Service, Departments of Gynecology and Obstetrics and Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD

In Reply:

Dr Markman raises a number of important issues with respect to our recent article describing the risk of ovarian cancer recurrence in the presence of a rising serum cancer antigen 125 level within the normal range.1 Unlike the primary management of ovarian cancer, management of recurrent disease is a highly individualized process, both from the perspective of the individual patient as well as the individual clinician. Our clinical practice employs a proactive approach toward early detection of recurrence and consideration to secondary cytoreductive surgery for patients with appropriate selection criteria. Among the criteria we use to identify appropriate candidates for secondary tumor cytoreduction are the patient performance status, the disease-free interval, and the focality and extent of recurrent disease. Several retrospective studies have now shown that patients most likely to benefit from secondary cytoreductive surgery will have localized small volume disease.2-5 In addition, the utility of combined positron emission tomography/computed tomography for detecting recurrent ovarian cancer when conventional imaging studies are negative or equivocal is now readily apparent.6 We certainly acknowledge that many clinicians treating women with ovarian cancer do not subscribe to this approach, and we appreciate Dr Markman's willingness to offer an alternative treatment paradigm.

Authors' Disclosures of Potential Conflicts of Interest

The authors indicated no potential conflicts of interest.

REFERENCES

1. Santillan A, Garg R, Zahurak ML, et al: Risk of epithelial ovarian recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 23:9338-9343, 2005[Abstract/Free Full Text]

2. Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88:144-153, 2000[CrossRef][Medline]

3. Zang RY, Zhang ZY, Li ZT, et al: Impact of secondary cytoreduction surgery on survival of patients with advanced epithelial ovarian cancer. Eur J Surg Oncol 26:798-804, 2000[CrossRef][Medline]

4. Tay E, Grant PT, Gebski V, et al: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 99:1008-1013, 2002[CrossRef][Medline]

5. Onda T, Yoshikawa H, Yasugi T, et al: Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: Proposal for patients selection. Br J Cancer 92:1026-1032, 2005[CrossRef][Medline]

6. Bristow RE, del Carmen MG, Pannu HK, et al: Clinically occult recurrent ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 90:519-528, 2003[CrossRef][Medline]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santillan, A.
Right arrow Articles by Bristow, R. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Santillan, A.
Right arrow Articles by Bristow, R. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online